Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22723600 | 0.92 | JAK1 (0.45) | JAK1PDK4SCN9AGPR119TNK2 | |
| SCHEMBL21796999 | 0.92 | RXRA (0.40) | JAK1PDK4GPR119RXRARXRB | |
| SCHEMBL21796837 | 0.91 | TNF (0.46) | JAK1PDK4SCN9ATNK2GRM5 | |
| SCHEMBL21796772 | 0.88 | JAK1 (0.42) | JAK1PDK4SCN9AGPR119TNK2 | |
| SCHEMBL23478560 | 0.88 | RXRA (0.44) | JAK1GRM5RXRARXRBRXRG | |
| SCHEMBL23297984 | 0.87 | RXRA (0.38) | JAK1GPR119RXRARXRBRXRG | |
| SCHEMBL24638317 | 0.86 | RXRA (0.51) | JAK1SCN9AGPR119TNK2GRM5 | |
| SCHEMBL21796569 | 0.86 | NAMPT (0.45) | JAK1PDK4SCN9AGPR119TNK2 | |
| SCHEMBL21894615 | 0.83 | JAK1 (0.47) | JAK1PDK4SCN9AKITHTR6 | |
| SCHEMBL23779872 | 0.83 | JAK1 (0.43) | JAK1PDK4SCN9AGRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873471-A1 | N-HETEROARYL INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-108137510-B | Compound (I) | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-07-20 | — | — | CN | disclosed |
| US-11034696-B2 | Compounds for inhibiting LRRK2 kinase activity | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| US-20210130339-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3325449-B1 | HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
| EP-3325449-B1 | HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
| US-10858367-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-10858367-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20200079777-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
| WO-2018137619-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018137593-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018137607-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858367-B2 | Compounds | LRRK2, PARK7, PINK1 | JAK1 2813/4885PDK4 494/4885SCN9A 2329/4885 |
| US-20210130339-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | JAK1 2813/4885PDK4 494/4885SCN9A 2329/4885 |
| US-11034696-B2 | Compounds for inhibiting LRRK2 kinase activity | LRRK2, BRSK2, MAPKAPK2 | JAK1 392/4885PDK4 578/4885SCN9A 596/4885 |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | LRRK2, PARK7, PINK1 | JAK1 952/4885PDK4 186/4885SCN9A 2434/4885 |
| US-20200079777-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | JAK1 2837/4885PDK4 459/4885SCN9A 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.